Sentiment-Signal
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 07.03.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | “Affiliate Registration Rights Agreement” in Item 5.02 and incorporated herein by reference. Item 5.02 Departure of Di |
| 26.03.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ow in accordance with clauses (c), (d) and (e) of Item 5.02 of Form 8-K. Patel Second Amended and Restated Employment |
| 19.09.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Comp |
| 20.07.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Co |
| 05.06.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Co |
| 18.05.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ed by specific reference in such filing. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; |
Stammdaten
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Unternehmen & Branche
| Name | Replimune Group, Inc. |
|---|---|
| Ticker | REPL |
| CIK | 0001737953 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 200,7 Mio. USD |
| Beta | 0,74 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-Q | -70,930,000 | -0.77 | 333,590,000 | 210,539,000 | |
| 2025-09-30 | 10-Q | -83,100,000 | -0.90 | 389,450,000 | 263,336,000 | |
| 2025-06-30 | 10-Q | -86,693,000 | -0.95 | 469,507,000 | 336,715,000 | |
| 2025-03-31 | 10-K | -247,297,000 | -3.07 | 551,328,000 | 415,843,000 | |
| 2024-12-31 | 10-Q | -66,340,000 | -0.79 | 603,628,000 | 482,374,000 | |
| 2024-09-30 | 10-Q | -53,055,000 | -0.68 | 498,202,000 | 381,459,000 | |
| 2024-06-30 | 10-Q | -53,772,000 | -0.78 | 534,965,000 | 426,451,000 | |
| 2024-03-31 | 10-K | -215,794,000 | -3.24 | 487,722,000 | 374,508,000 | |
| 2023-12-31 | 10-Q | -51,120,000 | -0.77 | 532,930,000 | 421,537,000 | |
| 2023-09-30 | 10-Q | -60,044,000 | -0.90 | 562,398,000 | 465,172,000 | |
| 2023-06-30 | 10-Q | -49,555,000 | -0.75 | 603,891,000 | 514,029,000 | |
| 2023-03-31 | 10-K | -174,284,000 | -2.99 | 646,591,000 | 555,292,000 | |
| 2022-12-31 | 10-Q | -39,690,000 | -0.69 | 678,550,000 | 595,345,000 | |
| 2022-09-30 | 10-Q | -43,102,000 | -0.79 | 436,095,000 | 384,072,000 | |
| 2022-06-30 | 10-Q | -42,253,000 | -0.78 | 459,427,000 | 410,262,000 | |
| 2022-03-31 | 10-K | -118,036,000 | -2.26 | 461,192,000 | 411,229,000 | |
| 2021-12-31 | 10-Q | -29,674,000 | -0.57 | 485,282,000 | 437,509,000 | |
| 2021-09-30 | 10-Q | -29,355,000 | -0.56 | 503,464,000 | 457,412,000 | |
| 2021-06-30 | 10-Q | -27,311,000 | -0.53 | 523,724,000 | 479,024,000 | |
| 2021-03-31 | 10-K | -21,499,000 | -1.75 | 543,098,000 | 498,728,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-12-09 | Dhingra Kapil | Director | Open Market Sale | -3,169 | 10.40 | -32,957.60 | -39,8% | |
| 2025-12-02 | Patel Sushil | Director, Officer, Chief Executive Officer | Open Market Sale | -10,000 | 11.13 | -111,300.00 | -134,5% | |
| 2025-11-17 | Xynos Konstantinos | Officer, Chief Medical Officer | Open Market Sale | -7,248 | 9.10 | -65,956.80 | -79,7% | |
| 2025-11-17 | Sarchi Christopher | Officer, Chief Commercial Officer | Open Market Sale | -5,208 | 9.10 | -47,392.80 | -57,3% | |
| 2025-08-15 | Hill Emily Luisa | Officer, Chief Financial Officer | Open Market Sale | -9,154 | 5.37 | -49,156.98 | -59,4% | |
| 2025-05-20 | Astley-Sparke Philip | Director | Open Market Sale | -32,279 | 8.06 | -260,168.74 | -314,3% | |
| 2025-05-20 | Sarchi Christopher | Officer, Chief Commercial Officer | Open Market Sale | -3,749 | 8.05 | -30,179.45 | -36,5% | |
| 2025-05-20 | Patel Sushil | Director, Officer, Chief Executive Officer | Open Market Sale | -25,105 | 8.06 | -202,346.30 | -244,5% | |
| 2025-05-20 | Xynos Konstantinos | Officer, Chief Medical Officer | Open Market Sale | -7,952 | 8.06 | -64,093.12 | -77,4% | |
| 2025-05-20 | Hill Emily Luisa | Officer, Chief Financial Officer | Open Market Sale | -2,535 | 8.05 | -20,406.75 | -24,7% | |
| 2025-05-20 | Schwendenman Andrew | Officer, Chief Accounting Officer | Open Market Sale | -3,287 | 8.05 | -26,460.35 | -32,0% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.